For Healthcare Professionals

Treatment of Patients With Newly Diagnosed Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumor, or Atypical Teratoid Rhabdoid Tumor

clipboard-pencil

About the study

Drugs used in chemotherapy, such as vincristine, cisplatin, and cyclophosphamide, work in different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining radiation therapy with chemotherapy may kill more tumor cells. Autologous stem cell transplant may be able to replace blood-forming cells that were destroyed by chemotherapy or radiation therapy. It is not yet known which radiation therapy regimen combined with chemotherapy and donor stem cell transplant is more effective in treating medulloblastoma, supratentorial primitive neuroectodermal tumor, or atypical teratoid rhabdoid tumor. This phase III trial is studying two different regimens of radiation therapy when given together with chemotherapy and autologous stem cell transplant to see how well they work in treating patients with newly diagnosed medulloblastoma, supratentorial primitive neuroectodermal tumor, or atypical teratoid rhabdoid tumor. PRIMARY OBJECTIVE: - To assess the relationship between ERBB2 protein expression in tumors and progression-free survival probability for patients with medulloblastoma. - To estimate the frequency of mutations associated with SHH and WNT tumors (as defined by gene expression profiling) via targeted sequencing performed in an independent cohort of WNT and SHH tumors (also defined by gene expression profiling).
user-3

Who can take part

You may be eligible to participate in the study if you meet the following criteria:

INCLUSION CRITERIA

    EXCLUSION CRITERIA

      pin location

      Study Locations

      Enter your ZIP code/Postal code/PIN code to locate study sites near you:

      How to Apply


      Contact the study center to learn if this study is a good match for you.
      Phone iconCall 866-278-5833Email iconEmail Study Center

      Study’s details


      Contition

      Brain and Central Nervous System Tumors

      Age

      3+

      Phase

      Phase 3

      Participants needed

      416

      Est. Completion Date

      Dec 2023

      Treatment type

      Interventional


      Sponsor

      St. Jude Children's Research Hospital

      ClinicalTrials.gov identifier

      NCT00085202

      Study number

      SJMB03

      Understanding Clinical Trials


      Get answers to your questions about clinical trials.What is a clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?
      Vector

      Interested?

      Sign up to save your favorites, 
      receive newsletters, resources, and alerts 
      about clinical trials related to your conditions of interest.